New data revealed that nearly 100 percent (99%) of 200 U.S. primary care physicians surveyed agree that heart disease and stroke are the number one cause of death and disability among type 2 diabetes patients; however, almost 40 percent (36%) of these physicians underestimate the number of patients who die from cardiovascular disease. Furthermore, while people with diabetes are two to four times more likely to have heart disease than people without diabetes, the survey, conducted by Harris Interactive and supported by Merck, found only one out of five (21%) patients (n=664) listed heart attack or heart failure as their biggest worry regarding diabetes complications, and even fewer patients (7%) listed stroke.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/merck/50638/
For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, “you are not alone.” Lilly Diabetes understands the importance of the diabetes camp experience for those taking the first steps toward self-management and increased self-confidence. For more than 15 years, Lilly has been at the forefront of support with its Camp Care Package program. This year, Lilly’s diabetes ambassadors, all of whom have type 1 diabetes, will attend camps and share their stories starting July 4 at the Children with Diabetes® Friends for Life® conference.
To view the multimedia release go to:
https://www.multivu.com/players/English/8115051-lilly-diabetes-camp-care-package-speaker-tour/
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
Eli Lilly and Company (NYSE: LLY) will commemorate its 140th anniversary today with activities at Lilly locations worldwide, including a ceremony to unveil a statue dedicated to founder Colonel Eli Lilly at global headquarters in Indianapolis.
Over 14 decades, the organization has contributed more than 100 medicines and significant medical advances, such as the first commercially available insulin, manufacturing and global distribution of the Salk polio vaccine and mental health breakthroughs such as anti-depressant Prozac® (fluoxetine). Today Lilly continues to progress its most robust pipeline in history with dozens of potential new medicines in mid- to late-stage development for cancer, diabetes, autoimmune disease, pain and Alzheimer’s disease.
“As Lilly celebrates 140 years, we’re keeping the vision of our founder alive – from our dedication in the lab to our impact in the community,” said John C. Lechleiter, Ph.D., Lilly chairman, president and chief executive officer, who began his career at Lilly as a chemist in 1979. “Colonel Eli Lilly started this company to put science to work fighting disease and encouraged his successors to ‘take what you find here and make it better and better.’ That vision pushes us daily to honor Colonel Lilly’s legacy and continue in our quest to discover new medicines to help make life better.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7809951-eli-lilly-and-company-140th-anniversary/
Diabetes initiative and the global fight against the urban diabetes epidemic. These two major metropolitan centres are the first Chinese cites to become part of the global partnership programme, which was initiated in Mexico City in March 2014, followed by Copenhagen in Europe and Houston in the United States last week.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7377451-novo-nordisk-shanghai-diabetes/
Today, the newly-developed Body Volume Indicator (BVI)™ was revealed as a modern day measure of body composition and weight distribution following a 10-year collaboration with Mayo Clinic experts who led extensive research on fat distribution, the importance of fat assessment and the limitations of the current standard of Body Mass Index (BMI). In conjunction with the development of BVI, BVI America LLC, a subsidiary of 3D measurement pioneer Select Research, announced the launch of the revolutionary BVI Pro tablet application, which will provide an easily accessible and affordable means for the professional community to use the new BVI measurement in everyday clinical use to assess health risks.
The potential benefits of using Body Volume as a new indicator of risks were presented on April 27 by Mayo Clinic researchers, BVI America and the University of Westminster. It draws on 10 years of rigorous research, testing and validation using several potential Body Volume indices. Now BVI, calculated as a ratio between total volume and abdominal volume, can be used as a supplement to the current measurement standard of BMI, which is based solely on height and weight. BVI is considered to be a more precise means of estimating weight distribution and the fat around the organs, which is not visible to the human eye and can lead to serious health conditions, such as diabetes and heart disease. The medical and professional community at large is invited to contribute to the continued development of BVI by downloading and using the BVI Pro tablet application with their patients and clients; anonymous data collected will be analyzed by Mayo Clinic, whose research and validation of BVI will continue.
To view the multimedia release go to:
https://www.multivu.com/players/English/8093051-bvi-america-body-volume-app-health-fitness/
A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans. Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly reported that obesity is a risk factor, and less than one in five reported that diabetes and kidney disease are risk factors. GUAES released the survey findings in advance of its annual Gout Awareness Day on May 22.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gouteducation/49664/
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today issued a new challenge to the millions of Americans affected by type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. In 2015, award-winning artist Tim McGraw, celebrated actress S. Epatha Merkerson and chef Leticia Moreinos Schwartz each shared their personal connection to type 2 diabetes. This year, they’re calling on people to share their stories.
Living with diabetes isn’t easy, and that’s why America’s Diabetes Challenge encourages people with type 2 diabetes to work with their doctor to set and reach their A1C goal. The program will aim to identify the most common challenges patients submit and will offer tips to help address them. The program is also designed to help people learn if they’re at risk of low blood glucose, known as hypoglycemia, and how to help reduce that risk.
To view the multimedia release go to:
http://www.multivu.com/players/English/7785551-merck-americas-diabetes-challenge/
Diabetes experts met and determined that some self-monitoring blood glucose (SMBG) systems, despite meeting accuracy standards at the time of U.S. Food and Drug Administration (FDA) clearance, fail to consistently meet accuracy standards once on the market, potentially putting patient health at risk. In a public meeting convened by the Diabetes Technology Society on May 21, 2013, in Arlington, Virginia, leading academic clinicians, clinical chemists, medical device experts, patient advocates and FDA representatives reviewed a growing body of peer-reviewed research demonstrating that the performance of some blood glucose monitors on the market may not be meeting accuracy standards.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/61870-diabetes-technology-society-inaccurate-blood-glucose-monitors-risky
Blink Health, America’s leading prescription drug savings platform, today launched a program to help #TreatType2 diabetes by committing to give away $10 million worth of medication to patients with type-2 diabetes. People living with diabetes who create an account on Blink Health’s website or free mobile app, starting today, will receive a free, one-year supply of the three most commonly prescribed generic medications for type-2 diabetes: metformin, glipizide and pioglitazone. The program will also cover these three medications for existing Blink Health patients who use them.
To view the multimedia release go to:
https://www.multivu.com/players/English/8117451-blink-health-type-2-diabetes-medications/
Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11.
BELVIQ was approved by the U.S. Food and Drug Administration on June 27, 2012 to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of 30 kg/m² or greater (obese), or BMI of 27 kg/m² or greater (overweight) with at least one weight-related medical condition such as high blood pressure, high cholesterol, or type 2 diabetes. It is not known if BELVIQ is safe and effective when taken with other prescription, over-the-counter, or herbal weight loss products, nor is it known if BELVIQ changes your risk of heart problems or stroke, or of death due to heart problems or stroke.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults
People who don’t have diabetes think that they are ok. But the way so many people eat, they put themselves at risk for this disease. Eating a diet high in processed foods, high sugar, and simple carbohydrates increase your chances of Type II Diabetes and especially if you are overweight. Other risk factors for Type II Diabetes are elevated triglyceride, low HDL, and high blood pressure.
